PCC Rokita SA (WSE:PCR)
Poland · Delayed Price · Currency is PLN 70.20
+0.20 (0.29%)
Aug 8, 2025, 10:30 AM CET
Theseus Pharmaceuticals Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 1,947 | 2,388 | 3,143 | 2,203 | 1,476 | Upgrade | |
Revenue Growth (YoY) | -18.46% | -24.01% | 42.64% | 49.29% | -1.08% | Upgrade |
Cost of Revenue | 1,557 | 1,804 | 1,994 | 1,498 | 1,132 | Upgrade |
Gross Profit | 390.84 | 584.25 | 1,148 | 705.77 | 343.6 | Upgrade |
Selling, General & Admin | 283.75 | 297.91 | 364.47 | 272.28 | 215.54 | Upgrade |
Other Operating Expenses | -87.32 | -92.09 | -64.54 | -48.78 | -26.91 | Upgrade |
Operating Expenses | 196.44 | 205.83 | 299.93 | 223.5 | 188.63 | Upgrade |
Operating Income | 194.41 | 378.43 | 848.32 | 482.28 | 154.97 | Upgrade |
Interest Expense | -35.44 | -31.22 | -21.96 | -20.99 | -27.64 | Upgrade |
Interest & Investment Income | - | 12.36 | 4.91 | 2.32 | 6.73 | Upgrade |
Earnings From Equity Investments | 1.43 | 1.31 | 3.56 | 6.43 | 1.35 | Upgrade |
Currency Exchange Gain (Loss) | - | -35.73 | 4.09 | -1.77 | 4.45 | Upgrade |
Other Non Operating Income (Expenses) | - | -0.03 | -0.77 | -1.51 | -1.91 | Upgrade |
EBT Excluding Unusual Items | 160.4 | 325.12 | 838.15 | 466.76 | 137.96 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | 8.95 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | 0.15 | 6.61 | Upgrade |
Asset Writedown | - | - | - | - | -0.53 | Upgrade |
Legal Settlements | - | -11.47 | -24.44 | -0.09 | - | Upgrade |
Pretax Income | 160.4 | 313.65 | 813.72 | 466.82 | 152.98 | Upgrade |
Income Tax Expense | 17.33 | 45.77 | 138.63 | 49.5 | 35.58 | Upgrade |
Earnings From Continuing Operations | 143.07 | 267.88 | 675.09 | 417.32 | 117.41 | Upgrade |
Minority Interest in Earnings | -0.03 | -0.04 | -0.03 | -0.02 | -0.02 | Upgrade |
Net Income | 143.04 | 267.84 | 675.06 | 417.3 | 117.39 | Upgrade |
Net Income to Common | 143.04 | 267.84 | 675.06 | 417.3 | 117.39 | Upgrade |
Net Income Growth | -46.59% | -60.32% | 61.77% | 255.49% | 25.87% | Upgrade |
Shares Outstanding (Basic) | 20 | 20 | 20 | 20 | 20 | Upgrade |
Shares Outstanding (Diluted) | 20 | 20 | 20 | 20 | 20 | Upgrade |
EPS (Basic) | 7.21 | 13.49 | 34.00 | 21.02 | 5.91 | Upgrade |
EPS (Diluted) | 7.21 | 13.49 | 34.00 | 21.02 | 5.91 | Upgrade |
EPS Growth | -46.59% | -60.32% | 61.75% | 255.66% | 25.80% | Upgrade |
Free Cash Flow | 177.28 | 295.76 | 563.06 | 380.18 | 195.35 | Upgrade |
Free Cash Flow Per Share | 8.93 | 14.90 | 28.36 | 19.15 | 9.84 | Upgrade |
Dividend Per Share | - | 6.700 | 21.570 | 13.230 | 3.670 | Upgrade |
Dividend Growth | - | -68.94% | 63.04% | 260.49% | 7.63% | Upgrade |
Gross Margin | 20.07% | 24.46% | 36.54% | 32.03% | 23.28% | Upgrade |
Operating Margin | 9.98% | 15.85% | 26.99% | 21.89% | 10.50% | Upgrade |
Profit Margin | 7.34% | 11.21% | 21.48% | 18.94% | 7.95% | Upgrade |
Free Cash Flow Margin | 9.10% | 12.38% | 17.92% | 17.26% | 13.24% | Upgrade |
EBITDA | 373.33 | 537.92 | 1,020 | 637.6 | 289.46 | Upgrade |
EBITDA Margin | 19.17% | 22.52% | 32.47% | 28.94% | 19.61% | Upgrade |
D&A For EBITDA | 178.92 | 159.49 | 172.01 | 155.32 | 134.49 | Upgrade |
EBIT | 194.41 | 378.43 | 848.32 | 482.28 | 154.97 | Upgrade |
EBIT Margin | 9.98% | 15.85% | 26.99% | 21.89% | 10.50% | Upgrade |
Effective Tax Rate | 10.80% | 14.59% | 17.04% | 10.60% | 23.25% | Upgrade |
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.